Search Results
-
Tachycardia unraveled
Researchers engineered stem cell-derived heart tissues to study how tachycardia affects the heart and to uncover the inner workings of our body’s engine.
-
How statins improve vascular health
Statins designed to lower cholesterol have long been noted to work in mysterious ways to improve other aspects of cardiovascular health. A Stanford Medicine-led study uncovers how they do it.
-
Telomere length crucial in muscular dystrophy
Telomeres shorten in heart muscle cells from people with Duchenne muscular dystrophy. A Stanford Medicine study finds blocking this process improves the health of these cells grown in a dish.
-
Diabetes drug may treat heart disease
A genetic variant that inhibits alcohol metabolism harms blood vessel cells, but an antidiabetic medication may mitigate the harm, Stanford Medicine-led research has found.
-
Joseph Wu to be AHA president
Beginning July 2023, Wu will lead the nation’s largest nonprofit organization dedicated to advancing cardiovascular health.
-
$31 million for stem cell clinical trials
The California Institute for Regenerative Medicine has awarded $31 million to three Stanford researchers to launch trials of treatments for common diseases. Four other Stanford researchers also received a total of $4.55 million.
-
Possible cure for iron-overload disease
Motivated by the loss of a patient, a doctor leads a research effort to uncover the molecular mechanisms of hemochromatosis in the heart.
-
Unregulated artery cell growth may drive atherosclerosis
Unregulated cell growth seems to be a driver behind the growth of atherosclerotic plaques, changing the traditional story of plaque formation. The rapid cell growth in the arterial wall is similar to pre-cancerous growth in other tissues.
-
Nanotherapy reduces artery plaque in mice
Stanford researchers have found that drug-coated nanoparticles limit the development of atherosclerosis in mice, without side effects.
-
Possible drug target for cardiomyopathy
Stanford researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.